Supratek Pharma (Canada)

Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

Sarah Danson, D. Ferry, Valery Yu. Alakhov et al. · British Journal of Cancer · 2004 · 375 citations · Full text

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Juan W. Valle, Anne Armstrong, Chris Newman et al. · Investigational New Drugs · 2010 · 292 citations

Esophageal Cancer, Gastrointestinal Oncology, Medicine +7

Fundamental Relationships Between the Composition of Pluronic Block Copolymers and Their Hypersensitization Effect in MDR Cancer Cells

Elena V. Batrakova, Shengmin Lee, Shu Li et al. · Pharmaceutical Research · 1999 · 289 citations

Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials

Valery Yu. Alakhov, Evgueni Klinski, Shengmin Li et al. · Colloids and Surfaces B Biointerfaces · 1999 · 266 citations

Nanomedicine, Medicinal Chemistry, Polymer-drug Conjugate +9

Metastasis-associated Protein S100A4 Induces Angiogenesis through Interaction with Annexin II and Accelerated Plasmin Formation

Alexandre Semov, María Moreno, Anatoli Onichtchenko et al. · Journal of Biological Chemistry · 2005 · 232 citations · Full text